The psychosis of schizophrenia: Prevalence, response to atypical antipsychotics, and prediction of outcome

Alan Breier, Paul H. Berg

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations. Although psychosis is present in the majority of patients with schizophrenia, the prevalence, responsiveness to atypical antipsychotic drug therapy, and prediction of outcome of individual psychotic symptoms in a population of well-diagnosed patients with schizophrenia have not been conclusively established. Methods: This paper examined the prevalence, responsiveness to the atypical antipsychotic olanzapine, and relationship to outcome of individual psychotic symptoms using data from a previously reported large multicenter, double-blind clinical trial of olanzapine (mean daily dose at endpoint = 13.6 ± 6.9 mg/day). Results: The most frequently reported psychotic symptoms at baseline were delusions (65%), conceptual disorganization (50%), and hallucinations (52%), and the majority of patients (68%) experienced from one to three symptoms. Additionally, with olanzapine treatment there were significant improvements (p <.001) in baseline to endpoint Positive and Negative Symptom Scale (PANSS) psychotic item scores, with the largest effect sizes observed for hallucinatory behavior, unusual thought content, suspiciousness/persecution, and delusions. During the acute phase of the trial, quality of life was correlated significantly with baseline conceptual disorganization (p = .038) and unusual thought content (p = .023), and time spent in the hospital was correlated with unusual thought content (p = .005). Conclusions: The implications of these for the clinical management of schizophrenia are discussed. Copyright (C) 1999 Society of Biological Psychiatry.

Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalBiological Psychiatry
Volume46
Issue number3
DOIs
StatePublished - Aug 1 1999

Fingerprint

olanzapine
Psychotic Disorders
Antipsychotic Agents
Delusions
Schizophrenia
Hallucinations
Quality of Life
Clinical Trials
Drug Therapy
Population

Keywords

  • Atypical antipsychotic
  • Olanzapine
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

The psychosis of schizophrenia : Prevalence, response to atypical antipsychotics, and prediction of outcome. / Breier, Alan; Berg, Paul H.

In: Biological Psychiatry, Vol. 46, No. 3, 01.08.1999, p. 361-364.

Research output: Contribution to journalArticle

@article{0bb34ad14a304dccbfb9b582e2278af4,
title = "The psychosis of schizophrenia: Prevalence, response to atypical antipsychotics, and prediction of outcome",
abstract = "Background: Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations. Although psychosis is present in the majority of patients with schizophrenia, the prevalence, responsiveness to atypical antipsychotic drug therapy, and prediction of outcome of individual psychotic symptoms in a population of well-diagnosed patients with schizophrenia have not been conclusively established. Methods: This paper examined the prevalence, responsiveness to the atypical antipsychotic olanzapine, and relationship to outcome of individual psychotic symptoms using data from a previously reported large multicenter, double-blind clinical trial of olanzapine (mean daily dose at endpoint = 13.6 ± 6.9 mg/day). Results: The most frequently reported psychotic symptoms at baseline were delusions (65{\%}), conceptual disorganization (50{\%}), and hallucinations (52{\%}), and the majority of patients (68{\%}) experienced from one to three symptoms. Additionally, with olanzapine treatment there were significant improvements (p <.001) in baseline to endpoint Positive and Negative Symptom Scale (PANSS) psychotic item scores, with the largest effect sizes observed for hallucinatory behavior, unusual thought content, suspiciousness/persecution, and delusions. During the acute phase of the trial, quality of life was correlated significantly with baseline conceptual disorganization (p = .038) and unusual thought content (p = .023), and time spent in the hospital was correlated with unusual thought content (p = .005). Conclusions: The implications of these for the clinical management of schizophrenia are discussed. Copyright (C) 1999 Society of Biological Psychiatry.",
keywords = "Atypical antipsychotic, Olanzapine, Psychosis, Schizophrenia",
author = "Alan Breier and Berg, {Paul H.}",
year = "1999",
month = "8",
day = "1",
doi = "10.1016/S0006-3223(99)00040-2",
language = "English (US)",
volume = "46",
pages = "361--364",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - The psychosis of schizophrenia

T2 - Prevalence, response to atypical antipsychotics, and prediction of outcome

AU - Breier, Alan

AU - Berg, Paul H.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Background: Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations. Although psychosis is present in the majority of patients with schizophrenia, the prevalence, responsiveness to atypical antipsychotic drug therapy, and prediction of outcome of individual psychotic symptoms in a population of well-diagnosed patients with schizophrenia have not been conclusively established. Methods: This paper examined the prevalence, responsiveness to the atypical antipsychotic olanzapine, and relationship to outcome of individual psychotic symptoms using data from a previously reported large multicenter, double-blind clinical trial of olanzapine (mean daily dose at endpoint = 13.6 ± 6.9 mg/day). Results: The most frequently reported psychotic symptoms at baseline were delusions (65%), conceptual disorganization (50%), and hallucinations (52%), and the majority of patients (68%) experienced from one to three symptoms. Additionally, with olanzapine treatment there were significant improvements (p <.001) in baseline to endpoint Positive and Negative Symptom Scale (PANSS) psychotic item scores, with the largest effect sizes observed for hallucinatory behavior, unusual thought content, suspiciousness/persecution, and delusions. During the acute phase of the trial, quality of life was correlated significantly with baseline conceptual disorganization (p = .038) and unusual thought content (p = .023), and time spent in the hospital was correlated with unusual thought content (p = .005). Conclusions: The implications of these for the clinical management of schizophrenia are discussed. Copyright (C) 1999 Society of Biological Psychiatry.

AB - Background: Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations. Although psychosis is present in the majority of patients with schizophrenia, the prevalence, responsiveness to atypical antipsychotic drug therapy, and prediction of outcome of individual psychotic symptoms in a population of well-diagnosed patients with schizophrenia have not been conclusively established. Methods: This paper examined the prevalence, responsiveness to the atypical antipsychotic olanzapine, and relationship to outcome of individual psychotic symptoms using data from a previously reported large multicenter, double-blind clinical trial of olanzapine (mean daily dose at endpoint = 13.6 ± 6.9 mg/day). Results: The most frequently reported psychotic symptoms at baseline were delusions (65%), conceptual disorganization (50%), and hallucinations (52%), and the majority of patients (68%) experienced from one to three symptoms. Additionally, with olanzapine treatment there were significant improvements (p <.001) in baseline to endpoint Positive and Negative Symptom Scale (PANSS) psychotic item scores, with the largest effect sizes observed for hallucinatory behavior, unusual thought content, suspiciousness/persecution, and delusions. During the acute phase of the trial, quality of life was correlated significantly with baseline conceptual disorganization (p = .038) and unusual thought content (p = .023), and time spent in the hospital was correlated with unusual thought content (p = .005). Conclusions: The implications of these for the clinical management of schizophrenia are discussed. Copyright (C) 1999 Society of Biological Psychiatry.

KW - Atypical antipsychotic

KW - Olanzapine

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0032765604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032765604&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(99)00040-2

DO - 10.1016/S0006-3223(99)00040-2

M3 - Article

C2 - 10435201

AN - SCOPUS:0032765604

VL - 46

SP - 361

EP - 364

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 3

ER -